Wenlafaksyna – właściwości farmakologiczne oraz zastosowanie w praktyce klinicznej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2018
Słowa kluczowe:
wenlafaksyna, depresja, zaburzenia lękowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Wenlafaksyna jest lekiem z grupy inhibitorów wychwytu zwrotnego serotoniny i noradrenaliny, obecnym w praktyce klinicznej od ponad 20 lat. Aktualnie stosowana jest głównie w leczeniu zaburzeń depresyjnych i lękowych. (…) Dzięki korzystnym właściwościom farmakologicznym, zadowalającej skuteczności oraz tolerancji leczenia wenlafaksyna jest jednym z najczęściej stosowanych leków przeciwdepresyjnych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gorostowicz, A., & Siwek , M. (2018). Wenlafaksyna – właściwości farmakologiczne oraz zastosowanie w praktyce klinicznej . Medycyna Faktów , 11(3(40), 199-205. https://doi.org/10.24292/01.MF.0318.6
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. [online: www.accessdata.fda.gov].
2. Rybakowski J., Jaracz J.: Farmakologiczne i kliniczne własności wenlafaksyny, nowego leku przeciwdepresyjnego. Farmakoter. Psychiatr. Neurol. 2000; 1: 83-96.
3. [online: https://bazalekow.mp.pl/].
4. Cascade E.F., Kalali A.H., Thase M.E.: Use of Antidepressants. Expansion Beyond Depression and Anxiety. Psychiatry (Edgmont) 2007; 4(12): 25-28.
5. GBD 2015; Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053): 1545-1602.
6. [online: http://www.who.int/en/news-room/fact-sheets/detail/depression].
7. Greenberg P.E., Fournier A.A., Sisitsky T. et al.: The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J. Clin. Psychiatry 2015; 76(2): 155-162.
8. Gałązka-Sobotka M. (red.): Depresja – analiza kosztów ekonomicznych i społecznych. Instytut Zarządzania w Ochronie Zdrowia, Warszawa 2014.
9. Cipriani A., Furukawa T.A., Salanti G. et al.: Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391(10128): 1357-1366.
10. Magalhães P., Alves G., LLerena A. et al.: Clinical drug-drug interactions: focus on venlafaxine. Drug Metab. Pers. Ther. 2015; 30(1): 3-17.
11. Gutierrez M.A., Stimmel G.L., Aiso J.Y.: Venlafaxine: a 2003 update. Clin. Ther. 2003; 25(8): 2138-2154.
12. Debonnel G., Saint-André E., Hébert C. et al.: Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int. J. Neuropsychopharmacol. 2007; 10(1): 51-61.
13. Stahl S.M. (red.): Stahl’s Essential Psychopharmacology. Cambridge University Press, New York 2013.
14. [online: https://www.pfizermedicalinformation.com/en-us/effexor-xr/clinical-pharmacology].
15. Cipriani A., Signoretti A., Furukawa T.A. et al.: Venlafaxine versus other anti-depressive agents for depression. Cochrane Database Syst. Rev. 2007; (2).
16. Carvalho A.F., Sharma M.S., Brunoni A.R. et al.: The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother. Psychosom. 2016; 85(5): 270-288.
17. Bazire S.: Psychotropic Drug Directory 2018. Lloyd-Reinhold Publications, London 2018.
18. Harrison C.L., Ferrier N., Young A.H.: Tolerability of high-dose venlafaxine in depressed patients. J. Psychopharmacol. 2004; 18(2): 200-204.
19. Mbaya P., Alam F., Ashim S. et al.: Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum. Psychopharmacol. 2007; 22(3): 129-133.
20. Thase M.E.: Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J. Clin. Psychiatry 1998; 59(10): 502-508.
21. Martinez C., Assimes T.L., Mines D. et al.: Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ 2010; 340: c249.
22. McIntyre R.S., Park K.Y., Law C.W. et al.: The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 2010; 24(9): 741-753.
23. Domecq J.P., Prutsky G., Leppin A. et al.: Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis. J. Clin. Endocrinol. Metab. 2015; 100(2): 363-370.
24. Ah-Kee E.Y., Egong E., Shafi A. et al.: A review of drug-induced acute angle closure glaucoma for non-ophthalmologists. Qatar. Med. J. 2015; 2015(1): 6.
25. Botha V.E., Bhikoo R., Merriman M.: Venlafaxine-induced intraocular pressure rise in a patient with open angle glaucoma. Clin. Exp. Ophthalmol. 2016; 44(8): 734-735.
26. Telles-Correia D., Barbosa A., Cortez-Pinto H. et al.: Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J. Gastrointest. Pharmacol. Ther. 2017; 8(1): 26-38.
27. Friedrich M.E., Akimova E., Huf W. et al.: Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program. Int. J. Neuropsychopharmacol. 2016; 19(4).
28. Waade R.B., Hermann M., Moe H.L. et al.: Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur. J. Clin. Pharmacol. 2014; 70(8): 933-940.
29. Ho J.M., Gomes T., Straus S.E. et al.: Adverse cardiac events in older patients receiving venlafaxine: a population-based study. J. Clin. Psychiatry 2014; 75(6): e552-558.
30. Spina E., Santoro V., D’Arrigo C.: Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin. Ther. 2008; 30(7): 1206-1227.
31. Spina E., Trifirò G., Caraci F.: Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26(1): 39-67.
32. Woroń J., Siwek M.: Unwanted effects of psychotropic drug interactions with medicinal products and diet supplements containing plant extracts. Psychiatr. Pol. Online first 2018; 92: 1-15.
33. Cunningham L.A.: Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann. Clin. Psychiatry 1997; 9(3): 157-164.
34. Rudolph R.L., Feiger A.D.: A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J. Affect. Disord. 1999; 56(2-3): 171-181.
35. Schweizer E., Feighner J., Mandos L.A. et al.: Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J. Clin. Psychiatry 1994; 55(3): 104-108.
36. Thase M.E.; The Venlafaxine XR 209 Study Group: Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J. Clin. Psychiatry 1997; 58(9): 393-398.
37. Higuchi T., Kamijima K., Nakagome K. et al.: A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan. Int. Clin. Psychopharmacol. 2016; 31(1): 8-19.
38. Watanabe K., Thase M.E., Kikuchi T. et al.: Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study. Int. Clin. Psychopharmacol. 2017; 32(5): 271-280.
39. Bauer M., Tharmanathan P., Volz H.P. et al.: The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2009; 259(3): 172-185.
40. Thase M., Asami Y., Wajsbrot D. et al.: A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder. Curr. Med. Res. Opin. 2017; 33(2): 317-326.
41. Tundo A., de Filippis R., Proietti L.: Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. World J. Psychiatry 2015; 5(3): 330-341.
42. Allgulander C., Mangano R., Zhang J. et al.: Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum. Psychopharmacol. 2004; 19(6): 387-396.
43. Stein M.B., Pollack M.H., Bystritsky A. et al.: Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacology (Berl) 2005; 177: 280-288.
44. Liebowitz M.R., Gelenberg A.J., Munjack D.: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry 2005A; 62(2): 190-198.
45. Liebowitz M.R., Mangano R.M., Bradwejn J. et al.; SAD Study Group: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 2005; 66: 238-247.
46. Rickels K., Mangano R., Khan A.: A double-blind, placebocontrolled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J. Clin. Psychopharmacol. 2004; 24: 488-496.
47. Davidson J.R., DuPont R.L., Hedges D. et al.: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J. Clin. Psychiatry 1999; 60(8): 528-535.
48. Rickels K., Pollack M.H., Sheehan D.V. et al.: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. J. Psychiatry 2000; 157(6): 968-974.
49. Gelenberg A.J., Lydiard R.B., Rudolph R.L. et al.: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 2000; 283(23): 3082-3088.
50. Allgulander C., Hackett D., Salinas E.: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry 2001; 179: 15-22.
51. Li X., Zhu L., Su Y. et al.: Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis. PLoS One 2017; 12(10): e0185865.
52. Andrisano C., Chiesa A., Serretti A.: Newer antidepressants and panic disorder: a meta-analysis. Int. Clin. Psychopharmacol. 2013; 28(1): 33-45.
53. Jarema M. (red.): Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Wyd. 2. Via Medica, Gdańsk 2015.
54. Charakterystyka produktu leczniczego: wenlafaksyna
2. Rybakowski J., Jaracz J.: Farmakologiczne i kliniczne własności wenlafaksyny, nowego leku przeciwdepresyjnego. Farmakoter. Psychiatr. Neurol. 2000; 1: 83-96.
3. [online: https://bazalekow.mp.pl/].
4. Cascade E.F., Kalali A.H., Thase M.E.: Use of Antidepressants. Expansion Beyond Depression and Anxiety. Psychiatry (Edgmont) 2007; 4(12): 25-28.
5. GBD 2015; Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053): 1545-1602.
6. [online: http://www.who.int/en/news-room/fact-sheets/detail/depression].
7. Greenberg P.E., Fournier A.A., Sisitsky T. et al.: The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J. Clin. Psychiatry 2015; 76(2): 155-162.
8. Gałązka-Sobotka M. (red.): Depresja – analiza kosztów ekonomicznych i społecznych. Instytut Zarządzania w Ochronie Zdrowia, Warszawa 2014.
9. Cipriani A., Furukawa T.A., Salanti G. et al.: Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391(10128): 1357-1366.
10. Magalhães P., Alves G., LLerena A. et al.: Clinical drug-drug interactions: focus on venlafaxine. Drug Metab. Pers. Ther. 2015; 30(1): 3-17.
11. Gutierrez M.A., Stimmel G.L., Aiso J.Y.: Venlafaxine: a 2003 update. Clin. Ther. 2003; 25(8): 2138-2154.
12. Debonnel G., Saint-André E., Hébert C. et al.: Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int. J. Neuropsychopharmacol. 2007; 10(1): 51-61.
13. Stahl S.M. (red.): Stahl’s Essential Psychopharmacology. Cambridge University Press, New York 2013.
14. [online: https://www.pfizermedicalinformation.com/en-us/effexor-xr/clinical-pharmacology].
15. Cipriani A., Signoretti A., Furukawa T.A. et al.: Venlafaxine versus other anti-depressive agents for depression. Cochrane Database Syst. Rev. 2007; (2).
16. Carvalho A.F., Sharma M.S., Brunoni A.R. et al.: The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother. Psychosom. 2016; 85(5): 270-288.
17. Bazire S.: Psychotropic Drug Directory 2018. Lloyd-Reinhold Publications, London 2018.
18. Harrison C.L., Ferrier N., Young A.H.: Tolerability of high-dose venlafaxine in depressed patients. J. Psychopharmacol. 2004; 18(2): 200-204.
19. Mbaya P., Alam F., Ashim S. et al.: Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum. Psychopharmacol. 2007; 22(3): 129-133.
20. Thase M.E.: Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J. Clin. Psychiatry 1998; 59(10): 502-508.
21. Martinez C., Assimes T.L., Mines D. et al.: Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ 2010; 340: c249.
22. McIntyre R.S., Park K.Y., Law C.W. et al.: The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 2010; 24(9): 741-753.
23. Domecq J.P., Prutsky G., Leppin A. et al.: Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis. J. Clin. Endocrinol. Metab. 2015; 100(2): 363-370.
24. Ah-Kee E.Y., Egong E., Shafi A. et al.: A review of drug-induced acute angle closure glaucoma for non-ophthalmologists. Qatar. Med. J. 2015; 2015(1): 6.
25. Botha V.E., Bhikoo R., Merriman M.: Venlafaxine-induced intraocular pressure rise in a patient with open angle glaucoma. Clin. Exp. Ophthalmol. 2016; 44(8): 734-735.
26. Telles-Correia D., Barbosa A., Cortez-Pinto H. et al.: Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J. Gastrointest. Pharmacol. Ther. 2017; 8(1): 26-38.
27. Friedrich M.E., Akimova E., Huf W. et al.: Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program. Int. J. Neuropsychopharmacol. 2016; 19(4).
28. Waade R.B., Hermann M., Moe H.L. et al.: Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur. J. Clin. Pharmacol. 2014; 70(8): 933-940.
29. Ho J.M., Gomes T., Straus S.E. et al.: Adverse cardiac events in older patients receiving venlafaxine: a population-based study. J. Clin. Psychiatry 2014; 75(6): e552-558.
30. Spina E., Santoro V., D’Arrigo C.: Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin. Ther. 2008; 30(7): 1206-1227.
31. Spina E., Trifirò G., Caraci F.: Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26(1): 39-67.
32. Woroń J., Siwek M.: Unwanted effects of psychotropic drug interactions with medicinal products and diet supplements containing plant extracts. Psychiatr. Pol. Online first 2018; 92: 1-15.
33. Cunningham L.A.: Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann. Clin. Psychiatry 1997; 9(3): 157-164.
34. Rudolph R.L., Feiger A.D.: A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J. Affect. Disord. 1999; 56(2-3): 171-181.
35. Schweizer E., Feighner J., Mandos L.A. et al.: Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J. Clin. Psychiatry 1994; 55(3): 104-108.
36. Thase M.E.; The Venlafaxine XR 209 Study Group: Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J. Clin. Psychiatry 1997; 58(9): 393-398.
37. Higuchi T., Kamijima K., Nakagome K. et al.: A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan. Int. Clin. Psychopharmacol. 2016; 31(1): 8-19.
38. Watanabe K., Thase M.E., Kikuchi T. et al.: Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study. Int. Clin. Psychopharmacol. 2017; 32(5): 271-280.
39. Bauer M., Tharmanathan P., Volz H.P. et al.: The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2009; 259(3): 172-185.
40. Thase M., Asami Y., Wajsbrot D. et al.: A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder. Curr. Med. Res. Opin. 2017; 33(2): 317-326.
41. Tundo A., de Filippis R., Proietti L.: Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. World J. Psychiatry 2015; 5(3): 330-341.
42. Allgulander C., Mangano R., Zhang J. et al.: Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum. Psychopharmacol. 2004; 19(6): 387-396.
43. Stein M.B., Pollack M.H., Bystritsky A. et al.: Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacology (Berl) 2005; 177: 280-288.
44. Liebowitz M.R., Gelenberg A.J., Munjack D.: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry 2005A; 62(2): 190-198.
45. Liebowitz M.R., Mangano R.M., Bradwejn J. et al.; SAD Study Group: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 2005; 66: 238-247.
46. Rickels K., Mangano R., Khan A.: A double-blind, placebocontrolled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J. Clin. Psychopharmacol. 2004; 24: 488-496.
47. Davidson J.R., DuPont R.L., Hedges D. et al.: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J. Clin. Psychiatry 1999; 60(8): 528-535.
48. Rickels K., Pollack M.H., Sheehan D.V. et al.: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. J. Psychiatry 2000; 157(6): 968-974.
49. Gelenberg A.J., Lydiard R.B., Rudolph R.L. et al.: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 2000; 283(23): 3082-3088.
50. Allgulander C., Hackett D., Salinas E.: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry 2001; 179: 15-22.
51. Li X., Zhu L., Su Y. et al.: Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis. PLoS One 2017; 12(10): e0185865.
52. Andrisano C., Chiesa A., Serretti A.: Newer antidepressants and panic disorder: a meta-analysis. Int. Clin. Psychopharmacol. 2013; 28(1): 33-45.
53. Jarema M. (red.): Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Wyd. 2. Via Medica, Gdańsk 2015.
54. Charakterystyka produktu leczniczego: wenlafaksyna